edaravone ALS
Selected indexed studies
- Edaravone May Prevent Ferroptosis in ALS. (Curr Drug Targets, 2020) [PMID:32077821]
- Current State and Future Directions in the Therapy of ALS. (Cells, 2023) [PMID:37296644]
- Tofersen for SOD1 ALS. (Neurodegener Dis Manag, 2024) [PMID:39330700]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Edaravone May Prevent Ferroptosis in ALS. (2020) pubmed
- Current State and Future Directions in the Therapy of ALS. (2023) pubmed
- Tofersen for SOD1 ALS. (2024) pubmed
- Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review. (2023) pubmed
- Edaravone in ALS. (2009) pubmed
- Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. (2019) pubmed
- Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. (2022) pubmed
- What can we learn from the edaravone development program for ALS? (2017) pubmed
- Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. (2017) pubmed
- Advances in Understanding and Treating Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review. (2023) pubmed